Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Ritivel
AddedJun 25, 2026
UpdatedJul 2, 2026
Ritivel

Ritivel

Seed

AI-native platform for Life-Sciences Documentation.

HQ
San Francisco, CA, US
Accelerator
Y Combinator logoY CombinatorW26
Overview
Compare
Fundraising
Employees

Ritivel is an AI-native workspace for regulatory and medical writing teams at life sciences companies. Every month a drug is delayed from reaching the market costs pharma companies ~$45M in lost revenue and more importantly, delays treatment for thousands of patients who need it. Yet regulatory teams are stuck in a painful, months-long process: synthesizing thousands of pages of clinical data, hunting through SharePoint folders for the right documents, chasing colleagues for missing inputs, and manually drafting submissions.

Ritivel deploys AI agents that transform how regulatory teams work. Every data point includes citations linked back to the original source, so reviewers can verify with one click. Connected to SharePoint and Veeva, our agents automatically source the right documents.

Ritivel - Similar Companies

Raycaster logo

Raycaster

raycaster.ai

Rhizome AI logo

Rhizome AI

rhizomeai.com

Hippo Scribe logo

Hippo Scribe

gethipposcribe.com

Adentris logo

Adentris

adentris.com

Substrate logo

Substrate

substrate.cc

Baseline AI logo

Baseline AI

baselinetrials.com

Synthio Labs logo

Synthio Labs

synthiolabs.com

Complir logo

Complir

complir.io

Regbase logo

Regbase

regbase.com

The Synthesis Company logo

The Synthesis Company

Panacea logo

Panacea

withpanacea.com

Revnu logo

Revnu

revnu.com

Quantstruct logo

Quantstruct

quantstruct.com

Promptless logo

Promptless

promptless.ai

Convexia logo

Convexia

convexia.bio

Ritivel - Quick Facts

Who are Ritivel's competitors?

Companies similar to Ritivel include Raycaster, Rhizome AI, Hippo Scribe and Adentris.

Where is Ritivel's headquarters located?

Ritivel's headquarters is located in San Francisco, CA, US.

When was Ritivel's last funding round?

Ritivel's most recent funding round was for $500k (USD) in January 2026.

How much has Ritivel raised to-date?

As of Jan 1, 2026, Ritivel has raised a total of $500k (USD).